VBL Therapeutics has opened its new gene therapy manufacturing plant in Modiin, Israel, which will serve as the commercial facility for production of the company’s lead candidate, ofranergene obadenovec (VB-111), a gene-based biologic for solid tumor indications, pending approval. The Modiin facility is the first commercial-scale gene therapy manufacturing facility in Israel with 20,000 sq.-ft. of designated space capable of manufacturing large-scale capacity of 1,000 liters and is scalable t...